Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Stomach and esophageal cancer
Zanidatamab (dual HER2 bispecific; ECD2/4) + chemo in 1L HER2+ mGEA shows early ERBB2 ctDNA clearance tied to 12.5-mo mPFS
Zanidatamab is a dual HER2-targeted bispecific antibody (binding HER2 extracellular domains 2 and 4) evaluated with platinum/fluoropyrimidine chemotherapy (mFOLFOX6, CAPOX, or 5-FU/cisplatin) in a Phase 2, 1L HER2+…
NCT03929666 - Trial result Spotlight
Stomach and esophageal cancer
Durvalumab (PD-L1 blockade) + perioperative FLOT boosts EFS across completion strata in resectable G/GEJ cancer (MATTERHORN)
Durvalumab (anti–PD-L1 monoclonal antibody) was added to perioperative FLOT (5-FU/leucovorin/oxaliplatin/docetaxel) in MATTERHORN, a global, double-blind Phase 3 trial in untreated, resectable…
NCT04592913 - Trial result Spotlight
Bladder and urothelial cancer
Ave + SG (TROP2 ADC) extends PFS across visceral/liver/bone subgroups vs avelumab alone in 1L maintenance aUC
Avelumab is a PD-L1 inhibitor, and sacituzumab govitecan (SG) is a TROP2-directed ADC delivering SN-38; this randomized Phase 2 JAVELIN Bladder Medley trial (NCT05327530) tested Ave + SG vs avelumab monotherapy as 1L…
NCT05327530 - Trial result Spotlight
Bladder and urothelial cancer
LY4052031 (Nectin-4 topo1 ADC) delivers 48% ORR in metastatic urothelial cancer, including post-enfortumab activity
LY4052031 is a next-generation anti–Nectin-4 antibody-drug conjugate (ADC) with a cleavable linker and a novel topoisomerase I inhibitor payload (Camp98; DAR 8) evaluated in the NEXUS-01 Phase 1 dose-escalation study…
NCT06465069 - Trial result Spotlight
Bladder and urothelial cancer
Enfortumab vedotin (Nectin-4 ADC) + pembrolizumab (PD-1) delivers ~57% pCR and halves death risk in cisplatin-ineligible MIBC
Enfortumab vedotin (a Nectin-4–directed MMAE antibody–drug conjugate) plus pembrolizumab (anti–PD-1) was evaluated as perioperative (neoadj-adj) therapy in the Phase 3 KEYNOTE-905/EV-303 randomized trial…
NCT03924895 - Trial result Spotlight
Bladder and urothelial cancer
Erdafitinib (pan-FGFR inhibitor) delivers 55% CR chemoablation in FGFR3-mutant recurrent NMIBC
Oral erdafitinib, a pan-FGFR1–4 tyrosine kinase inhibitor approved in metastatic urothelial carcinoma, was tested as short “chemoablation” in a Phase II window-of-opportunity study before TURBT in recurrent…
NCT04917809 - Trial result Spotlight
Brain and CNS tumors
Vorasidenib (dual mutant IDH1/2 inhibitor) delivers ~50-month PFS and delays next intervention in grade 2 IDH-mutant glioma
Vorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant IDH1/2, evaluated in the global, randomized, double-blind Phase 3 INDIGO trial (NCT04164901) in residual/recurrent grade 2 IDH1/2-mutant…
NCT04164901 - Trial result Spotlight
Ovarian cancer
Azenosertib (WEE1 inhibitor) + weekly paclitaxel delivers 39% ORR in platinum-resistant ovarian cancer
Azenosertib (ZN-c3) is an oral, selective WEE1 kinase inhibitor designed to exploit replication stress and impair DNA-damage checkpoint control; in the MUIR Phase 1b open-label dose-escalation trial (NCT04516447), it…
NCT04516447 - Trial result Spotlight
Ovarian cancer
Relacorilant (glucocorticoid receptor antagonist) + nab-paclitaxel extends OS by 4.1 months in platinum-resistant ovarian cancer
Relacorilant is a first-in-class, selective glucocorticoid receptor (GR) antagonist intended to counter GR-mediated chemotherapy resistance, and was combined with weekly nab-paclitaxel in the Phase 3 ROSELLA trial…
NCT05257408 - Trial result Spotlight
Ovarian cancer
TUB-040 (NaPi2b Exatecan ADC) Delivers 61% cORR in Platinum-Resistant Ovarian Cancer
TUB-040 is a NaPi2b-targeted antibody–drug conjugate with a DAR8 exatecan topoisomerase I payload via a cleavable P5 linker, evaluated as every-3-week monotherapy in biomarker-unselected platinum-resistant ovarian…
NCT06303505 - Trial result Spotlight
Prostate cancer
CAN-2409 (HSV‑tk adenoviral gene therapy) + valacyclovir improves DFS when added to curative EBRT in localized prostate cancer
Aglatimagene besadenovec (CAN-2409) is an intraprostatic, replication-defective adenoviral vector expressing HSV‑thymidine kinase; with valacyclovir it drives tumor cell kill and immunogenic cell death, and was…
NCT01436968 - Trial result Spotlight
Prostate cancer
Apalutamide (androgen receptor inhibitor) + perioperative ADT improves 5-year MFS in high-risk localized/locally advanced prostate cancer undergoing prostatectomy
Apalutamide is an oral androgen receptor pathway inhibitor added to standard androgen-deprivation therapy (ADT) to intensify perioperative systemic control around radical prostatectomy. In the Phase 3 double-blind…
NCT03767244 - Trial result Spotlight
Prostate cancer
Talazoparib (PARP inhibitor) + enzalutamide (AR inhibitor) boosts 3-year PFS to 77% in HRR-altered mHSPC
Talazoparib is an oral PARP1/2 inhibitor combined with enzalutamide, a potent androgen-receptor signaling inhibitor, on top of ADT in TALAPRO-3 (Phase 3, double-blind; NCT04821622) for metastatic androgen pathway…
NCT04821622 - Trial result Spotlight
Prostate cancer
ABBV-969 (PSMA/STEAP1 dual-targeting Top1i ADC) drives 45% ORR and 67% PSA50 in heavily pretreated mCRPC
ABBV-969 is a first-in-class dual-targeting antibody–drug conjugate (ADC) against PSMA and STEAP1 delivering a topoisomerase-1 inhibitor payload, evaluated as Q3W monotherapy in the Phase 1 FIH dose-escalation study…
NCT06318273 - Trial result Spotlight
Head and neck cancer
NBTXR3 (hafnium oxide radioenhancer) + SBRT reirradiation followed by anti–PD-1 drives 48% ORR in recurrent/metastatic HNSCC
NBTXR3 is an intratumoral hafnium oxide nanoparticle “radioenhancer” designed to locally amplify radiation effects and potentially augment immune priming; in Study 1100 (Phase I dose escalation/expansion;…
NCT03589339 - Trial result Spotlight
Head and neck cancer
Pembrolizumab (PD-1) + Definitive RT Improves 2-Year PFS vs Cisplatin CRT in Unfavorable-Risk p16+ HNSCC (KEYCHAIN)
KEYCHAIN was an open-label, randomized Phase II trial across 6 US academic centers testing definitive RT (70 Gy/35 fx) plus concurrent/adjuvant pembrolizumab (anti–PD-1; 200 mg starting 2 weeks pre-RT, then q3w up to…
- Trial result Spotlight
Head and neck cancer
Tosposertib (TGFβRI/VEGFR2 inhibitor) + pembrolizumab drives 75% ORR in 1L R/M HNSCC
Tosposertib (TU2218) is an oral dual TGFβRI/ALK5 and VEGFR2 inhibitor designed to counter TGF-β–mediated immune exclusion and angiogenesis, here combined with pembrolizumab (anti–PD-1) in an open-label, multicenter,…
NCT05784688 - Trial result Spotlight
Head and neck cancer
Ficerafusp alfa (EGFR×TGF-β trap) + pembrolizumab drives deeper shrinkage and ~10-mo mPFS in 1L HPV− R/M HNSCC
Ficerafusp alfa (BCA101) is a bifunctional EGFR-directed antibody engineered to trap TGF-β, combined here with pembrolizumab (anti–PD-1) in two Phase 1/1b first-line dose-expansion cohorts for PD-L1 CPS≥1,…
NCT04429542 - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 1 FH-WT1-E50 WT1-targeted TCR‑T plus azacitidine for MRD+ AML
This Phase 1 study at Fred Hutchinson Cancer Center evaluates FH‑WT1‑E50, an autologous CD4+/CD8+ T-cell product genetically transduced to express an HLA‑A02:01–restricted, WT1-specific T-cell receptor (TCR‑T; MOA:…
NCT07645469 First-in-human - New trial Spotlight
Ovarian cancer
Phase 1 GB-5267 IL-18–armored anti-MUC16 CAR T cell therapy in platinum-resistant ovarian cancer.
This first-in-human, open-label Phase 1 dose-escalation study tests GB-5267, an autologous CAR T-cell product engineered to recognize MUC16 (a surface antigen commonly expressed in epithelial ovarian cancers) and…
NCT07489287 First-in-human - New trial Spotlight
Pancreatic cancer
Phase 2 VS-7375 oral KRAS G12D (ON/OFF) inhibitor ± EGFR antibody cetuximab in metastatic PDAC.
Verastem, Inc. is running TARGET-D 201 (NCT07644559), an open-label, multicenter Phase 2 study testing VS-7375—an oral, KRAS G12D–selective “ON/OFF” small-molecule inhibitor—given as monotherapy and in combination…
NCT07644559 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 3 setidegrasib (ASP3082) KRAS G12D–targeted protein degrader vs docetaxel
Astellas Pharma Global Development is running this randomized, open-label Phase 3 study comparing setidegrasib (ASP3082) with docetaxel in adults with locally advanced unresectable or metastatic NSCLC harboring KRAS…
NCT07566052 Registrational - New trial Spotlight
Kidney cancer
Phase 3 belzutifan HIF-2α inhibitor + zanzalintinib MET/VEGFR TKI vs cabozantinib
Merck Sharp & Dohme (MSD) is running LITESPARK-033 (MK-6482-033), a Phase 3, randomized, open-label, multicenter study in recurrent advanced clear cell RCC after prior adjuvant anti–PD-1/PD-L1 therapy. Participants…
NCT07227402 Registrational - New trial Spotlight
Breast cancer
Phase 3 BGB-43395 CDK4-selective inhibitor plus letrozole vs CDK4/6 inhibitors in 1L HR+/HER2- MBC
This open-label, randomized, multicenter Phase 3 study (BeOne Medicines) tests whether BGB-43395—an oral, CDK4-selective small-molecule inhibitor—combined with letrozole (aromatase inhibitor) improves outcomes versus…
NCT07492641 Registrational - Trial result Spotlight
Breast cancer
T-DXd (HER2 ADC) + durvalumab (PD-L1) delivers ~83% ORR and ~38-month mPFS in 1L HER2+ mBC
Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody–drug conjugate (topoisomerase I payload), combined here with durvalumab, an anti–PD-L1 antibody, as first-line therapy in the DESTINY-Breast07 Phase 1b/2…
NCT04538742 - Trial result Spotlight
Breast cancer
T-DXd (HER2 ADC) + pertuzumab: CRs deepen slowly (8.4mo) but track with NC PFS in 1L HER2+ mBC
Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate (topoisomerase I payload) combined with pertuzumab (HER2 dimerization-blocking mAb) in the Phase 3 DESTINY-Breast09 first-line setting…
NCT04784715 - Trial result Spotlight
Breast cancer
Giredestrant (oral SERD/full ER antagonist) cuts recurrence risk in ER+/HER2– early breast cancer—benefit holds in pre- and postmenopause
Giredestrant (GIRE) is a next-generation oral selective estrogen receptor degrader (SERD) and full ER antagonist tested as 5-year adjuvant endocrine therapy in the global, randomized Phase III lidERA BC trial…
NCT04961996 - Trial result Spotlight
Breast cancer
Tucatinib (HER2 TKI) + trastuzumab/pertuzumab extends PFS as 1L HER2+ MBC maintenance—benefit holds across HR/BM subgroups
Tucatinib (TUC), an oral HER2-selective tyrosine kinase inhibitor, was evaluated in the Phase 3 HER2CLIMB-05 maintenance trial (NCT05132582) after induction taxane + trastuzumab/pertuzumab (HP) in HER2+ metastatic…
NCT05132582 - Trial result Spotlight
Breast cancer
Intratumoral DC1 (type 1 dendritic cell) immunotherapy + dual HER2 blockade drives 89% pCR in HR−/HER2+ early breast cancer
IT DC1 is an intratumoral conventional type 1 dendritic-cell (cDC1/DC1) therapy intended to inflame the tumor microenvironment; in the single-arm Phase 2 NATASHA trial (NCT05325632), patients with stage I–III HER2+…
NCT05325632 - Trial result Spotlight
Breast cancer
Dato-DXd (TROP2 ADC) extends PFS2/TFST/TSST vs chemo in 1L IO-ineligible metastatic TNBC
Datopotamab deruxtecan (Dato-DXd) is a TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload (deruxtecan); in the Phase 3, open-label TROPION-Breast02 trial (NCT05374512), previously…
NCT05374512
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.